NCIt definition : A proprietary recombinant bispecific T-cell engager (BiTE) antibody composed of two
single-chain variable fragments (scFv), one directed against the tumor-associated
antigen (TAA) CD33 fused to one that is directed against the CD3 antigen found on
T-lymphocytes, with potential immunostimulating and antineoplastic activities. Upon
administration of eluvixtamab, this bispecific antibody binds to both the CD3 antigen
on cytotoxic T-lymphocytes (CTLs) and the CD33 antigen found on CD33-expressing tumor
cells. This activates and redirects CTLs to CD33-expressing tumor cells, which results
in the CTL-mediated cell death of CD33-expressing tumor cells. CD33, a myeloid differentiation
antigen, is expressed on normal non-pluripotent hematopoietic stem cells and overexpressed
on neoplastic cells in patients with acute myeloid leukemia.;
UNII : 6Z4B5PJ4OP;
CAS number : 1679391-73-1; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 1679391-73-1
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;